Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Panthera Biopartners

Request full access

Clinical trial site management and patient recruitment services

Preston, United KingdomFounded 2019Biotech & Life Sciences

About Panthera Biopartners

Panthera Biopartners is the United Kingdom's largest independent Site Management Organization (SMO), specializing in conducting Phase II and Phase III clinical trials. Founded in July 2019 by Dr. Ian Smith, who previously founded the world's largest SMO, Synexus, and Professor John Lyon, a former global executive at CRO Covance, the company was established to manage clinical trials and patient recruitment for pharmaceutical companies and Contract Research Organizations (CROs).

The company's business model is centered on its network of dedicated clinical trial facilities across the UK, which provide services including trial planning, patient recruitment, data collection, and patient retention. Panthera serves a blue-chip client base that includes ten of the top twelve global pharmaceutical firms and seven of the top CROs. The firm generates revenue by running trials for these clients, addressing the critical industry challenge of efficient patient recruitment. Panthera operates sites in locations such as Glasgow, York, Sheffield, Preston, Rochdale, and Enfield. These sites are equipped with dedicated sample processing laboratories and are staffed by GCP-trained professionals.

Panthera has demonstrated rapid growth, securing its first institutional investment in 2020 and a further £10 million in 2022 to fund expansion across the UK and Western Europe. In August 2025, private equity firm LDC, part of Lloyds Banking Group, made a significant investment to support further international growth, marking a successful exit for previous investors BGF and Gresham House Ventures. The company has achieved significant milestones, including being the top global recruiter in four international studies in 2024. Its therapeutic expertise covers a broad range of areas traditionally managed in primary care, such as vaccines, cardiovascular disease, diabetes, neurology, respiratory medicine, and has expanded into specialist areas like oncology, NASH, and early dementia.

Source: Dealroom company data

At a glance

Status
Operational
Employees
143
Open positions
None listed
Dealroom signal
85.7/100
Industry
Health
Sub-industry
Pharmaceutical, Health Platform
Sector
Biotechnology, Clinical Trials, Hard Tech, Digital Pharma, DT and LS, uk is8 life sciences, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Apr 2026
Capital deployed
—
Preferred round
ACQUISITION

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GROWTH EQUITY VC✓Equity / VC Aug 2025 $0 — LDC ↗
EARLY VC✓Equity / VC Apr 2022 $13M $53M Business Growth Fund · Gresham House Ventures ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Panthera Biopartners website traffic

Latest recorded traffic for Panthera Biopartners is 170 monthly website visits, down 39.3% over the last three months. Panthera Biopartners's team grew 18.2% over the past year.

Latest monthly visits170 3-month web change-39.3% 1-year team growth+18.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Panthera Biopartners in the Preston ecosystem

Live from Dealroom

The Panthera Biopartners office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Gresham House Ventures
  • Business Growth Fund

Series B and later1 investor entered at this stage

  • LDC
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Panthera Biopartners on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Panthera Biopartners’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.